Vir Biotechnology lands a license agreement with Japan’s Astellas Pharma for its lead drug candidate.

Advanced Micro Devices rallies after the chip maker unveils a multi-year deal to supply computing power to Meta Platforms, ...

This player's pipeline should keep growth going over the long run.

Biotech hot picks spotlight Xenon, United Therapeutics and Axsome as Phase III data and FDA decisions approach.

If you're looking for a stock that may skyrocket, it's often important to start small. By this, I mean uncovering names that ...

Vir Biotechnology (VIR) is experiencing a surge of +58% pre-market due to a significant strategic partnership with Astellas concerning its prostate cancer ...

ImmunityBio's stock has roughly quintupled so far in 2026 as the company continues to deliver good news for investors.

AI-assisted drug discovery isn’t just science fiction anymore, especially as biotechnology and biopharma firms embrace the AI ...

Apogee Therapeutics (NASDAQ: APGE) is one of the 17 biotechnology stocks with more than 50% upside. On January 25, Citi analyst Geoff Meacham maintained a Buy rating on Apogee Therapeutics ...

Centessa Pharmaceuticals develops clinical-stage therapies for rare and serious diseases, leveraging a portfolio approach in ...

Journey Medical dermatology revenue plus Emrosi near-term sales and a rare pediatric disease PRV from Zycubo approval. See ...